The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer

BackgroundMutations in KRAS, BRAF, PIK3CA and PTEN expression have been in focus to predict the effect of epidermal growth factor receptor-blocking therapy in colorectal cancer (CRC). Here, information on these four aberrations was collected and combined to a Quadruple index and used to evaluate the prognostic role of these factors in CRC.PatientsWe analysed the mutation status in KRAS, BRAF and PIK3CA and PTEN expression in two separate CRC cohorts, Northern Sweden Health Disease Study (NSHDS; n=197) and Colorectal Cancer in Umeå Study (CRUMS; n=414). A Quadruple index was created, where Quadruple index positivity specifies cases with any aberration in KRAS, BRAF, PIK3CA or PTEN expression.ResultsQuadruple index positive tumours had a worse prognosis, significant in the NSHDS but not in the CRUMS cohort (NSHDS; P=0.003 and CRUMS; P=0.230) in univariate analyses but significance was lost in multivariate analyses. When analysing each gene separately, only BRAF was of prognostic significance in the NSHDS cohort (multivariate HR 2.00, 95% CI: 1.16–3.43) and KRAS was of prognostic significance in the CRUMS cohort (multivariate HR 1.48, 95% CI: 1.02–2.16). Aberrations in PIK3CA and PTEN did not add significant prognostic information.ConclusionsOur results suggest that establishment of molecular subgroups based on KRAS and BRAF mutation status is important and should be considered in future prognostic studies in CRC.

[1]  P. Kuppen,et al.  PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis , 2011, Cellular Oncology.

[2]  R. Ward,et al.  Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[4]  E. Riboli,et al.  Low folate levels may protect against colorectal cancer , 2006, Gut.

[5]  M. Loda,et al.  Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. , 2007, The Journal of molecular diagnostics : JMD.

[6]  P. Catalano,et al.  Association between DNA Methylation and Shortened Survival in Patients with Advanced Colorectal Cancer Treated with 5-Fluorouracil–Based Chemotherapy , 2007, Clinical Cancer Research.

[7]  P. Laird,et al.  CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer , 2006, Nature Genetics.

[8]  D. Spiegelman,et al.  A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers. , 2009, Gastroenterology.

[9]  P. Laurent-Puig,et al.  Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. , 2008, Cancer research.

[10]  M. Kohonen-Corish,et al.  Low microsatellite instability is associated with poor prognosis in stage C colon cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  B. Iacopetta,et al.  CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  J. Jakić-Razumović,et al.  Mutation pattern of KRAS and BRAF oncogenes in colorectal cancer patients. , 2011, Neoplasma.

[13]  B. Leggett,et al.  Low level microsatellite instability may be associated with reduced cancer specific survival in sporadic stage C colorectal carcinoma , 2004, Gut.

[14]  Carl W. Miller,et al.  Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene. , 2007, Leukemia research.

[15]  W. Grady.  Genomic instability and colon cancer , 2004, Cancer and Metastasis Reviews.

[16]  Peter Kraft,et al.  PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Bardelli,et al.  Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer , 2009, Journal of the National Cancer Institute.

[18]  S. Andreola,et al.  PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  S. Bull,et al.  Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. , 2000, The New England journal of medicine.

[20]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Y. Samuels,et al.  Oncogenic PI3K and its role in cancer , 2006, Current opinion in oncology.

[22]  S. Kato,et al.  Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer , 2013, International Journal of Clinical Oncology.

[23]  S. Benlloch,et al.  Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology. , 2006, The Journal of molecular diagnostics : JMD.

[24]  J. Herman,et al.  Association between CpG island methylation and microsatellite instability in colorectal cancer. , 1997, Cancer research.

[25]  Nobuo Ochi,et al.  Loss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survival , 2008, BMC gastroenterology.

[26]  R. Palmqvist,et al.  The Role of the CpG Island Methylator Phenotype in Colorectal Cancer Prognosis Depends on Microsatellite Instability Screening Status , 2010, Clinical Cancer Research.

[27]  H. Stenmark,et al.  Aberrant receptor signaling and trafficking as mechanisms in oncogenesis. , 2007, Critical reviews in oncogenesis.

[28]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[29]  Xin Wang,et al.  KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer. , 2011, Oncology reports.

[30]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[31]  Reiko Nishihara,et al.  Imaging , Diagnosis , Prognosis Prognostic Role of PIK 3 CA Mutation in Colorectal Cancer : Cohort Study and Literature Review , 2012 .

[32]  Sabine Tejpar,et al.  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.

[33]  Tae Won Kim,et al.  KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials. , 2013, International journal of radiation oncology, biology, physics.

[34]  A. Bardelli,et al.  Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  D. Spiegelman,et al.  Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803 , 2011, Clinical Cancer Research.

[36]  L. Griškevičius,et al.  KRas and BRaf mutational status analysis from formalin-fixed, paraffin-embedded tissues using multiplex polymerase chain reaction-based assay. , 2010, Archives of pathology & laboratory medicine.

[37]  Hua-Chuan Zheng,et al.  PTEN expression and mutation in colorectal carcinomas. , 2009, Oncology reports.

[38]  F. Cavalli,et al.  PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients , 2007, British Journal of Cancer.

[39]  D. Choi,et al.  Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma , 2010, Histopathology.

[40]  R. Houlston,et al.  Systematic review of microsatellite instability and colorectal cancer prognosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Elena A. Manilich,et al.  BRAF Mutations in Colorectal Cancer Are Associated With Distinct Clinical Characteristics and Worse Prognosis , 2012, Diseases of the colon and rectum.

[42]  I. Nagtegaal,et al.  Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. , 2010, European journal of cancer.

[43]  L. Mazzucchelli,et al.  Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer , 2009, PloS one.

[44]  R. Wolff,et al.  Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. , 2005, Gastroenterology.

[45]  J. E. Boers,et al.  Concordance in KRAS and BRAF mutations in endoscopic biopsy samples and resection specimens of colorectal adenocarcinoma. , 2012, European journal of cancer.

[46]  L. Weinehall,et al.  Cardiovascular disease and diabetes in the Northern Sweden Health and Disease Study Cohort- evaluation of risk factors and their interactions , 2003, Scandinavian journal of public health. Supplement.